Skye Bioscience's shares surged 15% after emphasizing the safety of their obesity treatment compared to competitors. The company highlighted the absence of neuropsychiatric side effects in their trial, contrasting with Novo Nordisk's treatment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing